Rallybio Corp (NASDAQ: RLYB)’s stock price has plunge by 14.36relation to previous closing price of 0.64. Nevertheless, the company has seen a 8.48% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-02-11 that NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Pharmacokinetic (PK) and safety data from the second trimes.
Is It Worth Investing in Rallybio Corp (NASDAQ: RLYB) Right Now?
The 36-month beta value for RLYB is at -1.36. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RLYB is 20.47M, and currently, shorts hold a 1.65% of that float. The average trading volume for RLYB on March 19, 2025 was 68.76K shares.
RLYB’s Market Performance
The stock of Rallybio Corp (RLYB) has seen a 8.48% increase in the past week, with a -2.53% drop in the past month, and a -34.43% fall in the past quarter. The volatility ratio for the week is 14.06%, and the volatility levels for the past 30 days are at 10.20% for RLYB. The simple moving average for the last 20 days is 3.60% for RLYB stock, with a simple moving average of -32.45% for the last 200 days.
Analysts’ Opinion of RLYB
Jefferies, on the other hand, stated in their research note that they expect to see RLYB reach a price target of $1.50, previously predicting the price at $7. The rating they have provided for RLYB stocks is “Hold” according to the report published on February 07th, 2024.
H.C. Wainwright gave a rating of “Buy” to RLYB, setting the target price at $18 in the report published on April 17th of the previous year.
RLYB Trading at -9.20% from the 50-Day Moving Average
After a stumble in the market that brought RLYB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.77% of loss for the given period.
Volatility was left at 10.20%, however, over the last 30 days, the volatility rate increased by 14.06%, as shares sank -0.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.71% lower at present.
During the last 5 trading sessions, RLYB rose by +8.48%, which changed the moving average for the period of 200-days by -50.04% in comparison to the 20-day moving average, which settled at $0.7089. In addition, Rallybio Corp saw -23.50% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RLYB
Current profitability levels for the company are sitting at:
- -95.12 for the present operating margin
- 0.89 for the gross margin
The net margin for Rallybio Corp stands at -90.84. The total capital return value is set at -0.98. Equity return is now at value -68.85, with -62.89 for asset returns.
Based on Rallybio Corp (RLYB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -320.01.
Currently, EBITDA for the company is -60.5 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 26.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.87.
Conclusion
In conclusion, Rallybio Corp (RLYB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
